| Journal of Translational Medicine | 卷:24 |
| The mitochondrial protease, LonP1, is a potential cardioprotective target for attenuating doxorubicin-induced cardiomyocyte death | |
| Research | |
| Kienan P. O’Dwyer1,2  Perry E. Bauer1,3  Sebastian A. Dziadowicz3,4  Subhankhi Pal1  Mark Eminhizer1,5  Aishwarya Bandaru1,6  Emma Myers1,7  Maan Awad8,9  Abdulrahman Murshid10  Matthew Santer8,9  Lei Wang3  Gangqing Hu3,11  Kathleen Brundage3,11  Evan DeVallance1,2  John M. Hollander1,5  Brijesh Patel8,9,12  Sundararajan Venkatesh1,5  | |
| [1] Department of Cardiovascular and Thoracic Surgery, West Virginia University School of Medicine, Morgantown, WV, USA | |
| [2] Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA | |
| [3] West Virginia Clinical and Translational Science Institute, Morgantown, WV, USA | |
| [4] Mitochondria, Metabolism, and Bioenergetics Working Group, West Virginia University School of Medicine, Morgantown, WV, USA | |
| [5] Mary Babb Cancer Institute, West Virginia University, Morgantown, WV, USA | |
| [6] Department of Physiology, Pharmacology, and Toxicology, West Virginia University School of Medicine, Morgantown, WV, USA | |
| [7] Division of Cardiology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA | |
| [8] Department of Medicine, West Virginia University School of Medicine, Morgantown, WV, USA | |
| [9] Heart and Vascular Institute, West Virginia University School of Medicine, Morgantown, WV, USA | |
| [10] Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA | |
| [11] Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA | |
| [12] Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA | |
| 关键词: Doxorubicin; Cardiotoxicity; Mitochondria; Apoptosis; Inflammation; TLR9; cGAS-STING; mtDNA; LonP1; | |
| DOI : 10.1186/s12967-026-08537-9 | |
| received in 2026-02-19, accepted in 2026-06-20, 发布年份 2026 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundDoxorubicin (DOX), a first-line chemotherapeutic agent, has been linked to severe off-target cardiotoxicity in the clinic. Previous works suggest that mitochondria are key mediators of this cardiotoxicity. Leakage of mitochondrial contents after DOX treatment, including mitochondrial DNA (mtDNA), is thought to activate apoptotic and inflammatory signaling pathways implicated in cardiomyocyte cell death. Whether the master mitochondrial protease, LonP1, can dampen these pathways and improve cardiomyocyte viability following DOX treatment remains unknown.MethodsHuman cardiac cells (AC-16) and primary (1°) human cardiomyocytes were subjected to DOX treatment, followed by bulk RNA-Seq, RT-qPCR, qPCR, and immunoblotting to assess apoptotic signaling, inflammatory signaling, mtDNA release, and LonP1 expression, respectively. Lentivirus transduction of AC-16 cells was used to generate both knockdown (KD) and overexpression (OE) LonP1 cell lines to determine the effects of altered LonP1 levels on DOX-induced apoptosis and mtDNA release. Further, levels of mitochondrial DNA (mtDNA) were measured using qPCR from serum samples obtained from patients undergoing DOX treatment to assess the clinical relevance of released mtDNA as a potential biomarker for the development of DOX cardiotoxicity.ResultsDOX treatment of AC-16 cells, as well as 1° human cardiomyocytes, upregulated both apoptotic and inflammatory signaling in both cell models. Increased LonP1 levels were also observed under DOX treatment in AC-16 cells and 1° human cardiomyocytes. Likewise, DOX increased mtDNA release from both cell lines, both prior to, and as a sequel to cell death. Decreasing LonP1 levels exacerbated DOX-mediated apoptotic signaling and mtDNA release, whereas overexpression of LonP1 attenuated these effects. Furthermore, DOX treatment in cancer patients increases plasma mtDNA levels.ConclusionsThese findings suggest LonP1 plays a protective role in the heart following DOX treatment, supporting LonP1 as a potential novel therapeutic target for prevention of DOX cardiotoxicity. Patterns of mtDNA release within patients undergoing DOX treatment also highlight the potential of mtDNA as a potential biomarker and target for prevention of DOX cardiotoxicity, justifying the need for more extensive, prospectively monitored cohort studies to expand upon these findings and statistically model mtDNA release patterns.Graphical Abstract
【 授权许可】
CC BY-NC-ND
© The Author(s) 2026
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202609300001625ZK.pdf | 9384KB | ||
| Supporting File | 6548KB | Other | |
| Supporting File | 2000KB | Other | |
| Fig. 2 | 89KB | Image | |
| Fig. 4 | 76KB | Image | |
| Scheme 1 | 132KB | Image | |
| Fig. 1 | 1450KB | Image | |
| Fig. 3 | 486KB | Image | |
| Fig. 1 | 781KB | Image | |
| Fig. 3 | 170KB | Image | |
| TABLE 1 | 10KB | Table | |
| TABLE 2 | 11KB | Table | |
| Fig. 6 | 1525KB | Image | |
| Supporting File 2 | 15KB | Other |
【 图 表 】
Fig. 6
Fig. 3
Fig. 1
Fig. 3
Fig. 1
Scheme 1
Fig. 4
Fig. 2
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
- [60]
- [61]
- [62]
- [63]
- [64]
- [65]
- [66]
- [67]
- [68]
- [69]
- [70]
- [71]
- [72]
- [73]
- [74]
- [75]
- [76]
- [77]
- [78]
- [79]
- [80]
- [81]
PDF